Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Celadon Pharmaceuticals PLC ( (GB:CEL) ) is now available.
Celadon Pharmaceuticals has announced that its strategic collaboration with Danish company Valeos Pharma is successfully enhancing its operations by accelerating the supply of EU-GMP cannabis API products. The partnership is crucial for meeting Celadon’s European supply commitments, including a significant contract with Germany, expected to generate £26 million over three years. This collaboration positions Celadon to capitalize on the growing demand for medicinal cannabis in Europe, leveraging Valeos’ cultivation capacity and Celadon’s proprietary genetics and IP to drive new revenue streams.
More about Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company dedicated to the development, production, and sale of innovative cannabis-based medicines. They focus on improving the quality of life for chronic pain sufferers and exploring treatments for conditions like autism. Celadon operates a large EU-GMP approved facility and holds a Home Office license for commercial supply of pharmaceutical-grade cannabis products. They also have a stake in Kingdom Therapeutics, which is working on cannabinoid medicines for autism.
YTD Price Performance: 6.67%
Average Trading Volume: 56,550
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £11.02M
Find detailed analytics on CEL stock on TipRanks’ Stock Analysis page.